<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51819">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431598</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00059192</org_study_id>
    <nct_id>NCT02431598</nct_id>
  </id_info>
  <brief_title>Eovist vs. Dotarem Healthy Volunteer MRI</brief_title>
  <official_title>Randomized, Blinded, Placebo-controlled Crossover Study Assessing Association Between Gadolinium-based Contrast Agent Administration and Transient Dyspnea/Arterial Phase Motion Artifact</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate changes in volunteer breath-holding capacity in
      response to gadoxetate disodium (Eovist) administration, compared with saline, and
      gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study
      sites. These subjects will be given three, blinded, randomized injections while undergoing
      an MRI of their liver and holding their breath. During the scan, the subjects' oxygen
      saturation and heart rate will be closely monitored. Following the scan, the subjects will
      complete a questionnaire regarding the breath hold.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject breath hold capacity, as measured by number of seconds a subject can hold his/her breath</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject-reported dyspnea, a measured by questionnaire</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in O2 saturation</measure>
    <time_frame>baseline, following contrast administration, up to 5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulse rate</measure>
    <time_frame>baseline, following contrast administration, up to 5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of motion artifacts at arterial phase imaging</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of motion artifacts at arterial phase imaging, measured on a 1-5 scale</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Transient Severe Arterial Phase Motion</condition>
  <arm_group>
    <arm_group_label>Eovist (gadoxetate disodium)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dotarem (gadoterate dimeglumine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoxetate disodium</intervention_name>
    <arm_group_label>Eovist (gadoxetate disodium)</arm_group_label>
    <other_name>Eovist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoterate dimeglumine</intervention_name>
    <arm_group_label>Dotarem (gadoterate dimeglumine)</arm_group_label>
    <other_name>Dotarem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - normal renal function (serum eGFR &gt;60)

        Exclusion Criteria:

          -  renal impairment

          -  allergy to gadolinium-based contrast

          -  metallic implanted devices

          -  claustrophobia

          -  pregnant and lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mustafa Bashir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 3, 2015</lastchanged_date>
  <firstreceived_date>April 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
